ClinicalTrials.gg
WithdrawnNCT05532020Updated Oct 13, 2026

An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities

A Phase 2 interventional study of DCCR (diazoxide choline) extended-release tablets in SH2B1 Deficiency Obesity, Obesity Associated With PCSK1 Mutation (rs6232 Variant) and SIM1 Deficiency Obesity, sponsored by Soleno Therapeutics, Inc.. Withdrawn. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Soleno Therapeutics, Inc. (part of Neurocrine Biosciences) · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
Company Decision
Updated Oct 13, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
5 Years and older
Sex
All
01

Study summary

This is a phase 2 open-label, one-arm, clinical study to evaluate the efficacy and safety of DCCR (diazoxide choline) extended-release tablets over 1 year of treatment, in patients with genetic obesities.

Read the detailed description

Patients aged 5 years and older with obesity due to SH2B1 deficiency obesity, obesity associated with PCSK1 mutation (rs6232 variant), or SIM1 deficiency obesity will be enrolled into this phase 2 open-label clinical trial at a single clinical center in North America. All eligible participants will receive DCCR (diazoxide choline) extended-release tablets for 1 year.

02

Conditions studied

  • SH2B1 Deficiency Obesity
  • Obesity Associated With PCSK1 Mutation (rs6232 Variant)
  • SIM1 Deficiency Obesity

Browse trials for

Keywords

  • SH2B1 deficiency obesity
  • Obesity associated with PCSK1 mutation
  • (rs6232 variant)
  • SIM1 deficiency obesity
  • Genetic obesity
03

In context

Obesity

11,560 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Lead sponsor

Soleno Therapeutics, Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

First submitted before Soleno Therapeutics, Inc. became part of Neurocrine Biosciences.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Provide voluntary, written (parent(s) / legal guardian(s) of patient); provide voluntary, written assent (patients, as appropriate)
  • Genetically-confirmed diagnosis of SH2B1 deficiency obesity, obesity associated with PCSK1 mutation (rs6232 variant), or SIM1 deficiency obesity

Key Exclusion Criteria:

  • Have participated in an interventional clinical study (i.e., drug or device, approved drugs or device evaluated for unapproved use) within 60 days prior to Screening
  • Any known disease and/or condition, which would prevent, in the opinion of the Investigator, the patient from completing all study visits and assessments required by the protocol
  • Positive urine pregnancy test (in females of ) or females who are pregnant or breastfeeding, and/or plan to become pregnant or to breast-feed during or within 30 days after study participation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Open-label DCCR

    75 - 525 mg DCCR

    Drug: DCCR (diazoxide choline) extended-release tablets

Interventions

  • DrugDiazoxide cholineStudies of Diazoxide cholineDiazoxide choline pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All participants will be titrated over a four week period to the maintenance dose. Participants will take DCCR daily for up to 52 weeks.

    Also known as: DCCR

06

What researchers measure

Primary outcomes

  1. Proportion of participants who achieve at least 5% body weight reduction

    Proportion of participants who achieve at least 5% body weight reduction

    Time frame: Baseline to Week 26

Secondary outcomes

  1. Leptin

    Change from Baseline in serum leptin

    Time frame: Baseline to Week 26

  2. Fasting serum insulin

    Change in fasting serum insulin

    Time frame: Baseline to Week 26

  3. Body fat mass

    Change in body fat mass (DXA)

    Time frame: Baseline to Week 26

  4. Feelings of hunger

    Change in self-reported feelings of hunger measured on a visual analog scale (VAS), 0 - 100 with 0 being no feelings of hunger and 100 being the most extreme sensation of hunger

    Time frame: Baseline to Week 26

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2023; primary completion for Jan 2024, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2022
First posted
Sep 8, 2022
StartEst.
Jan 2023
Primary completionEst.
Jan 2024
CompletionEst.
Mar 2024
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Withdrawn Company Decision
changed Oct 13, 2026
Enrollment
30 (estimated)→0 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Status unknown→Withdrawn
    Why stopped Company Decision
    Enrollment 30 (estimated)→0 (actual)
    + 3 other changes: verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05532020
Responsible party
Sponsor
First posted
Sep 8, 2022
Start date
Jan 2023 (estimated)
Primary completion
Jan 2024 (estimated)
Completion
Mar 2024 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diazoxide choline

Start the discussion